OSE Immunotherapeutics signs a license option agreement with Servier to develop and commercialize the product Effi-7
World Pharma Today | February 20, 2017
OSE Immunotherapeutics SA announced that the company has entered into a worldwide license option agreement with Servier, an independent international pharmaceutical company, for the development and commercialization of OSE Immunotherapeutics’ Effi-7, an antagonist of the interleukin-7 receptor.